AIM
BIIB icon

Alambic Investment Management’s Biogen BIIB Stock Holding History

Alambic Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,318
Closed -$360K – 569
2017
Q1 		$360K Sell
1,318
-262
-17% -$74.1K 0.04% 469
2016
Q4 		$448K Hold
1,580
– – 0.08% 353
2016
Q3 		$495K Sell
1,580
-30
-2% -$8.88K 0.12% 288
2016
Q2 		$389K Buy
+1,610
New +$424K 0.1% 331

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's BIIB Position: Q2 2017 in Review

Alambic Investment Management sold out of Biogen (BIIB) in Q2 2017, closing a stake of 1,318 shares — an estimated $360K sold.

Alambic Investment Management first reported a position in BIIB in Q2 2016 and held it in 4 quarters. The position peaked at $495K in Q3 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Alambic Investment Management reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Alambic Investment Management sold 1,318 Biogen shares in Q2 2017, an estimated $360K.
  • Alambic Investment Management first reported a position in Biogen in Q2 2016 and held it in 4 quarters.
  • Alambic Investment Management's Biogen position peaked at $495K in Q3 2016.
  • 992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Alambic Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.